Ironwood Pharma

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ironwood Pharma excels in Q4 with LINZESS growth and pipeline advancements

Ironwood Pharmaceuticals delivered a strong performance in Q4 2022, driven by LINZESS's growth and pipeline progress. Strategic priorities emphasize profitability and portfolio strength, while challenges around pricing and data release plans require attention. Opportunities exist in expanding LINZESS sales, pediatric indications, and pipeline investments for future growth.

Ironwood Pharma excels in Q1 with LINZESS driving growth

Ironwood Pharma's Q1 2023 showcased strong LINZESS demand, revenue growth, and profitability. The company's strategic focus on LINZESS and innovative pipeline positions it well for sustained success amidst market challenges and growth opportunities.

Ironwood Pharma reports strong Q2 performance and growth opportunities

Ironwood Pharmaceuticals showcased strong performance in Q2 2023, driven by robust U.S. net sales and strategic acquisitions.
While facing challenges in managing the impact of the VectivBio acquisition on EBITDA, the company is well-positioned for growth.
Opportunities lie in expanding LINZESS sales, advancing pipeline candidates like apraglutide, and diversifying into new indications.
Overall, Ironwood's focus on maximizing key products, pipeline advancement, and financial management sets a positive trajectory.

Ironwood Pharma reports strong Q3 performance amidst strategic acquisitions

Ironwood Pharmaceuticals showcased strong performance driven by LINZESS and the acquisition of VectivBio for apraglutide.
While facing challenges in managing financial losses and addressing competitive pressures, Ironwood remains focused on growth opportunities and product development.
Opportunities lie in upcoming Phase III data for apraglutide, pediatric market expansion for LINZESS, and exploring new patient subgroups for apraglutide.

Ironwood Pharma excels in Q4, eyes pediatric market growth

Ironwood Pharmaceuticals showcased robust financial performance, strategic acquisitions, and a focus on pipeline assets during their Q4 2023 earnings call. While facing challenges in defining efficacy and pricing strategies, the company remains optimistic about growth opportunities in the GI market, particularly in the pediatric segment.

Ironwood Pharma reports Q1 growth, prepares for apraglutide launch

Ironwood Pharma's Q1 2024 performance reflects growth in LINZESS prescription volume and positive developments in its pipeline, despite challenges in net sales and guidance adjustments. The company's strategic focus on maximizing LINZESS and preparing for apraglutide's launch presents opportunities for future growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

VectivBio Holding AG

Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company.

Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion

Ironwood Pharmaceuticals Inc said on Monday it will acquire Switzerland-based drug developer VectivBio Holding AG for $1.15 billion to boost its portfolio of experimental digestive disorder drugs.

Ironwood Pharma to acquire VectivBio for $1.15 bln

Ironwood Pharmaceuticals Inc. IRWD, +2.45% said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT, +8.18% for $17 a share in cash, or a total of about $1 billion, net of VectivBio's cash and debt. The price is equal to a premium of about 80% over the volume-weighted average share price over the previous 90 trading days.

Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion

BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that they have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggr.

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 1:30 p.m. ET at the New York Hilton Midtown. A live audio webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prio.

Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented findings during the 2023 Digestive Disease Week® (DDW) meeting from a Phase III clinical trial on the potential of linaclotide for children and adolescents ages 6-17 years-old with functional constipation. Ironwood had previously announced topline data from this study in September 2022. The presented data at DDW, which provided a more detailed description of the trial results, were.

Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - CEO Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Boris Peaker - Cowen Jacob Hughes - Wells Fargo Securities Operator Good day, and welcome to the Ironwood Pharmaceuticals Q1 2023 Investor Update Conference Call. Today's call is being recorded [Operator Instructions].

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2023 Earnings Call Transcript

Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.

Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.21 per share a year ago.

Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its first quarter 2023 results and recent business performance. “We are off to a terrific start to the year, as the strong momentum of LINZESS continues,” said Tom McCourt, chief executive officer of Ironwood. “In the first quarter, LINZESS prescription demand increased over 10% year-over-year, with LINZESS achieving an all-time high in new-to-brand patient volume. We look for.

Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings during the 2023 Digestive Disease Week® (DDW) from studies on the potential of linaclotide for children and adolescents ages 6-17 years-old with functional constipation. DDW is being held from May 6 through May 9 in Chicago, IL. Functional constipation in children is defined as a condition with hard, infrequent bowel movements that are o.

Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 4, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood's website at www.

Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences: Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET at the Boston Marriott Copley Place Barclays Global Healthcare Conference on Tuesday, March 14, 2023 at 8:00 a.m.

Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences

Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q4 2022 Earnings Conference Call February 16, 2023 8:30 AM ET Company Participants Matt Roache - Director, IR Thomas McCourt - CEO & Director Michael Shetzline - Chief Medical Officer, SVP and Head, Research & Drug Development Sravan Emany - SVP, Principal Financial Officer & CFO Conference Call Participants David Amsellem - Piper Sandler & Co. Daniel Wolle - JPMorgan Chase & Co. Timothy Chiang - Capital One Securities Boris Peaker - Cowen and Company Operator Good day, and welcome to the Ironwood Pharmaceuticals Q4 and Full Year 2022 Investor Update Conference Call. Today's call is being recorded.

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2022 Earnings Call Transcript

Ironwood (IRWD) delivered earnings and revenue surprises of -3.57% and 3.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2022 results and recent business performance. “We performed well and made important progress across our strategic priorities in 2022,” said Tom McCourt, chief executive officer of Ironwood. “While full year LINZESS U.S.

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.

Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for LINZESS® (linaclotide) for the treatment of children and adolescents ages 6-17 years-old with functional constipation (FC).

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?

Editas Medicine

Exelixis

All three healthcare stocks are showing solid long-term potential.

3 No-Brainer Stocks to Buy Right Now for Less Than $25

BOSTON--( BUSINESS WIRE )--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call

BOSTON--( BUSINESS WIRE )--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated financial guidance for full year 2022 and announced financial guidance for full year 2023. The results were announced in advance of the Company's presentation at the 41st Annual J.P. Morgan Healthcare Conference, which will take place on Wednesday, January 11, 2023 at 9:00 a.m. PT / 12:00 p.m. ET.

Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance

BOSTON--( BUSINESS WIRE )--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time at The Westin St. Francis in San Francisco, CA.

Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON--( BUSINESS WIRE )--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 4:30 p.m. ET at the Lotte New York Palace.

News for Ironwood Pharma Stock (IRWD)